Arbutus Biopharma Corp

Healthcare · Biotechnology

4.30$ -4.2% vs. previous close Closing price · As of: Oct 7, 2026

Statements

Balance Sheet

Arbutus Biopharma Corp (ABUS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 274 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ABUS
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	515	276	268	255	240	237	270	277	245	228	209	193	117	106	103	98	131	137	146	135	166	204	237	216	204	195	191	177	159	144	150	160	140	132	117	103	98	95	277	274
Current Assets	152	133	120	106	91	129	175	158	144	129	112	100	94	94	88	86	121	128	137	83	127	161	173	158	141	151	153	159	142	132	136	148	133	127	117	103	97	94	277	274
Cash	27	23	30	24	15	54	12	10	22	37	84	79	90	32	26	46	97	52	79	31	78	109	81	47	24	31	41	27	18	26	43	63	32	36	37	37	22	18	24	19
Cash & Short-Term Investments	150	131	110	103	88	126	173	155	142	125	111	95	90	91	85	82	118	123	132	78	121	155	165	150	135	147	147	152	134	126	129	142	128	123	113	98	94	91	95	93
Receivables	0.7	0.7	8.3	1.3	1.1	0.9	1.2	1.7	0.9	1.4	1.2	1.5	2.5	1.2	1.1	1.1	1.1	1.3	1.3	1.3	1.7	0.9	1.3	2.0	1.8	1.4	2.7	3.2	2.8	1.8	2.1	2.1	1.6	2.4	1.2	1.0	0.9	1.7	1.3	180
Inventory	1.3	1.2	1.4	1.5	1.4	2.0	0.0	0.0	0.0	–	–	0.0	–	–	–	–	0.0	–	–	0.0	–	–	–	0.0	0.0	-2.9	-3.5	-2.6	-5.3	–	0.0	-6.2	–	–	–	–	–	–	–	–
Property, Plant & Equipment	4.1	6.9	11	13	13	12	12	11	10	10	9.7	9.4	9.2	8.7	8.2	7.7	7.3	6.9	6.6	9.0	6.4	6.0	5.7	7.4	5.2	5.1	4.9	5.4	–	–	–	–	–	–	–	–	–	–	–	–
Goodwill	163	24	24	24	24	24	24	22	22	22	22	22	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	196	99	99	99	99	59	59	59	44	44	44	44	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	98	73	79	79	72	55	38	39	30	28	28	28	34	33	29	32	34	35	32	35	35	35	71	63	58	59	47	42	39	38	36	38	34	34	38	20	20	18	17	15
Current Liabilities	8.4	11	11	12	8.2	15	10	12	13	11	8.8	8.8	8.8	7.8	4.0	6.3	7.6	9.5	6.7	8.8	10	11	32	30	28	33	25	25	22	22	20	23	19	16	19	5.0	5.2	6.0	5.1	3.4
Short-Term Debt	5.1	6.7	5.8	4.9	4.1	8.7	6.5	5.3	6.2	–	0.6	0.4	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.5	0.5	0.5	0.5	0.6	0.5	0.5	0.5	0.6	0.5
Accounts Payable	2.1	3.2	1.6	3.4	2.3	2.0	0.9	3.2	3.1	3.2	2.3	0.7	1.4	2.4	0.5	1.2	0.9	3.0	0.4	2.1	1.0	3.2	1.2	12	0.9	3.5	2.5	1.0	2.3	3.2	3.7	2.7	2.3	2.3	2.2	1.3	1.0	1.2	1.5	2.9
Long-Term Debt	0.0	12	12	12	12	12	0.0	0.0	0.0	–	3.3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	417	203	189	176	167	182	232	238	215	200	181	164	84	73	73	66	97	102	114	101	130	169	166	153	146	137	144	135	119	106	115	122	107	97	79	83	77	77	260	259
Retained Earnings	-432	-651	-670	-688	-700	-738	-758	-757	-784	-805	-831	-857	-943	-970	-987	-1,004	-1,026	-1,046	-1,066	-1,088	-1,112	-1,134	-1,150	-1,164	-1,182	-1,204	-1,220	-1,237	-1,257	-1,277	-1,295	-1,314	-1,334	-1,347	-1,371	-1,369	-1,376	-1,380	-1,210	-1,216
Shares Outstanding	54	54	54	55	55	55	55	56	55	56	56	57	57	68	68	70	79	93	93	97	101	101	148	149	151	154	162	166	168	168	176	188	189	190	191	192	192	192	195	197

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings